Ramani K, Hassan Q, Venkaiah B, Hasnain S E, Sarkar D P
Department of Biochemistry, University of Delhi South Campus, Benito Juarez Road, New Delhi-110021, India.
Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):11886-90. doi: 10.1073/pnas.95.20.11886.
Inspite of several stimulating developments in gene therapy, the formulation of a targeted gene delivery "vector" is still far from ideal. We have demonstrated the potential of reconstituted Sendai viral envelopes containing only the fusion glycoprotein (F-virosomes) in targeted delivery of reporter genes to liver cells of BALB/c mouse in vivo. The membrane fusion-mediated high efficiency of gene transfer to liver cells was ascertained following a critical evaluation of the level of the DNA, mRNA, and relevant proteins. Furthermore, the involvement of viral glycoprotein both as a unique natural ligand and as a membrane fusogen could lead to preferential transfection of parenchymal cell types of liver. The integration of transgenes in the mouse chromosomal DNA and its stable expression up to 4 mo after single i.v. administration of this gene carrier has bolstered its efficiency and novelty. Moreover, the F-virosomes did not elicit significant humoral immune response against the fusion protein in the injected animal. The findings reported here open up the possibility for considering "F-virosomes" as a promising "vehicle" for site-specific DNA delivery in gene therapy.
尽管基因治疗有多项振奋人心的进展,但靶向基因递送“载体”的构建仍远非理想状态。我们已证明,仅含融合糖蛋白的重组仙台病毒包膜(F-病毒体)在体内将报告基因靶向递送至BALB/c小鼠肝细胞方面具有潜力。在对DNA、mRNA和相关蛋白水平进行严格评估后,确定了膜融合介导的基因高效转移至肝细胞的情况。此外,病毒糖蛋白作为独特的天然配体和膜融合原的作用,可能导致肝脏实质细胞类型的优先转染。单次静脉注射这种基因载体后,转基因整合到小鼠染色体DNA中并稳定表达长达4个月,这增强了其效率和新颖性。此外,F-病毒体在注射动物体内未引发针对融合蛋白的显著体液免疫反应。此处报道的研究结果为将“F-病毒体”视为基因治疗中位点特异性DNA递送的一种有前景的“载体”开辟了可能性。